Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Nitin Bharat Charbe; Nikhil D Amnerkar; B Ramesh; Murtaza M Tambuwala; Hamid A Bakshi; Alaa A A Aljabali; Saurabh C Khadse; Rajendran Satheeshkumar; Saurabh Satija; Meenu Metha; Dinesh Kumar Chellappan; Garima Shrivastava; Gaurav Gupta; Poonam Negi; Kamal Dua; Flavia C Zacconi

doi:10.1016/j.apsb.2020.10.005

Small interfering RNA for cancer treatment: overcoming hurdles in delivery

Acta Pharm Sin B. 2020 Nov;10(11):2075-2109. doi: 10.1016/j.apsb.2020.10.005. Epub 2020 Oct 13.

Authors

Nitin Bharat Charbe^{1

2}, Nikhil D Amnerkar³, B Ramesh², Murtaza M Tambuwala⁴, Hamid A Bakshi⁴, Alaa A A Aljabali⁵, Saurabh C Khadse⁶, Rajendran Satheeshkumar¹, Saurabh Satija^{7

8}, Meenu Metha^{7

8}, Dinesh Kumar Chellappan⁹, Garima Shrivastava¹⁰, Gaurav Gupta¹¹, Poonam Negi¹², Kamal Dua^{7

12

13}, Flavia C Zacconi^{1

14}

Affiliations

¹ Departamento de Quimica Orgánica, Facultad de Química y de Farmacia, Pontificia Universidad Católica de Chile, Santiago 7820436, Chile.
² Sri Adichunchunagiri College of Pharmacy, Sri Adichunchunagiri University, BG Nagar, Karnataka 571418, India.
³ Adv V. R. Manohar Institute of Diploma in Pharmacy, Nagpur, Maharashtra 441110, India.
⁴ School of Pharmacy and Pharmaceutical Science, Ulster University, Coleraine, Northern Ireland BT52 1SA, UK.
⁵ Faculty of Pharmacy, Department of Pharmaceutics and Pharmaceutical Technology, Yarmouk University, Irbid 21163, Jordan.
⁶ Department of Pharmaceutical Chemistry, R.C. Patel Institute of Pharmaceutical Education and Research, Dist. Dhule, Maharashtra 425 405, India.
⁷ Discipline of Pharmacy, Graduate School of Health, University of Technology Sydney, NSW 2007, Australia.
⁸ School of Pharmaceutical Sciences, Lovely Professional University, Phagwara 144411 Punjab, India.
⁹ Department of Life Sciences, School of Pharmacy, International Medical University, Bukit Jalil 57000, Kuala Lumpur, Malaysia.
¹⁰ Department of Biochemical Engineering and Biotechnology, Indian Institute of Technology, Delhi, New Delhi 110016, India.
¹¹ School of Pharmacy, Suresh Gyan Vihar University, Jagatpura, Jaipur 302017, India.
¹² School of Pharmaceutical Sciences, Shoolini University of Biotechnology and Management Sciences, Solan 173229, India.
¹³ Priority Research Centre for Healthy Lungs, Hunter Medical Research Institute (HMRI) and School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW 2308, Australia.
¹⁴ Institute for Biological and Medical Engineering, Schools of Engineering, Medicine and Biological Sciences, Pontificia Universidad Católica de Chile, Santiago 4860, Chile.

Abstract

In many ways, cancer cells are different from healthy cells. A lot of tactical nano-based drug delivery systems are based on the difference between cancer and healthy cells. Currently, nanotechnology-based delivery systems are the most promising tool to deliver DNA-based products to cancer cells. This review aims to highlight the latest development in the lipids and polymeric nanocarrier for siRNA delivery to the cancer cells. It also provides the necessary information about siRNA development and its mechanism of action. Overall, this review gives us a clear picture of lipid and polymer-based drug delivery systems, which in the future could form the base to translate the basic siRNA biology into siRNA-based cancer therapies.

Keywords: 1,3-propanediol, PEG-b-PDMAEMA-b-Ppy; 2-propylacrylicacid, PAH-b-PDMAPMA-b-PAH; APOB, apolipoprotein B; AQP-5, aquaporin-5; AZEMA, azidoethyl methacrylate; Atufect01, β-l-arginyl-2,3-l-diaminopropionicacid-N-palmityl-N-oleyl-amide trihydrochloride; AuNPs, gold nanoparticles; B-PEI, branched polyethlenimine; BMA, butyl methacrylate; CFTR, cystic fibrosis transmembrane conductance regulator gene; CHEMS, cholesteryl hemisuccinate; CHOL, cholesterol; CMC, critical micelles concentration; Cancer; DC-Chol, 3β-[N-(N′,N′-dimethylaminoethane)carbamoyl]cholesterol; DMAEMA, 2-dimethylaminoethyl methacrylate; DNA, deoxyribonucleic acid; DOPC, dioleylphosphatidyl choline; DOPE, dioleylphosphatidyl ethanolamine; DOTAP, N-[1-(2,3-dioleoyloxy)propyl]-N,N,N-trimethylammonium methyl-sulfate; DOTMA, N-[1-(2,3-dioleyloxy)propy]-N,N,N-trimethylammoniumchloride; DOX, doxorubicin; DSGLA, N,N-dis-tearyl-N-methyl-N-2[N′-(N2-guanidino-l-lysinyl)] aminoethylammonium chloride; DSPC, 1,2-distearoyl-sn-glycero-3-phosphocholine; DSPE, 1,2-distearoyl-sn-glycero-3-phosphorylethanolamine; DSPE-MPEG, 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] (ammonium salt); DSPE-PEG-Mal: 1,2-distearoyl-sn-glycero-3-phosphoethanolamine-N-[maleimide(polyethylene glycol)-2000] (mmmonium salt), EPR; Liposomes; Micelles; N-acetylgalactosamine, HIF-1α; Nanomedicine; PE-PCL-b-PNVCL, pentaerythritol polycaprolactone-block-poly(N-vinylcaprolactam); PLA, poly-l-arginine; PLGA, poly lactic-co-glycolic acid; PLK-1, polo-like kinase 1; PLL, poly-l-lysine; PPES-b-PEO-b-PPES, poly(4-(phenylethynyl)styrene)-block-PEO-block-poly(4-(phenylethynyl)styrene); PTX, paclitaxel; PiRNA, piwi-interacting RNA; Polymer; RES, reticuloendothelial system; RGD, Arg-Gly-Asp peptide; RISC, RNA-induced silencing complex; RNA, ribonucleic acid; RNAi, RNA interference; RNAse III, ribonuclease III enzyme; SEM, scanning electron microscope; SNALP, stable nucleic acid-lipid particles; SiRNA, short interfering rNA; Small interfering RNA (siRNA); S–Au, thio‒gold; TCC, transitional cell carcinoma; TEM, transmission electron microscopy; Tf, transferrin; Trka, tropomyosin receptor kinase A; USPIO, ultra-small superparamagnetic iron oxide nanoparticles; UV, ultraviolet; VEGF, vascular endothelial growth factor; ZEBOV, Zaire ebola virus; enhanced permeability and retention, Galnac; hypoxia-inducible factor-1α, KSP; kinesin spindle protein, LDI; lipid-protamine-DNA/hyaluronic acid, MDR; lysine ethyl ester diisocyanate, LPD/LPH; messenger RNA, MTX; methotrexate, NIR; methoxy polyethylene glycol-polycaprolactone, mRNA; methoxypoly(ethylene glycol), MPEG-PCL; micro RNA, MPEG; multiple drug resistance, MiRNA; nanoparticle, NRP-1; near-infrared, NP; neuropilin-1, PAA; poly(N,N-dimethylacrylamide), PDO; poly(N-isopropyl acrylamide), pentaerythritol polycaprolactone-block-poly(N-isopropylacrylamide); poly(acrylhydrazine)-block-poly(3-dimethylaminopropyl methacrylamide)-block-poly(acrylhydrazine), PCL; poly(ethylene glycol)-block-poly(2-dimethylaminoethyl methacrylate)-block poly(pyrenylmethyl methacrylate), PEG-b-PLL; poly(ethylene glycol)-block-poly(l-lysine), PEI; poly(ethylene oxide)-block-poly(2-(diethylamino)ethyl methacrylate)-stat-poly(methoxyethyl methacrylate), PEO-b-PCL; poly(ethylene oxide)-block-poly(Ε-caprolactone), PE-PCL-b-PNIPAM; poly(Ε-caprolactone), PCL-PEG; poly(Ε-caprolactone)-polyethyleneglycol-poly(l-histidine), PCL-PEI; polycaprolactone-polyethyleneglycol, PCL-PEG-PHIS; polycaprolactone-polyethylenimine, PDMA; polyethylenimine, PEO-b-P(DEA-Stat-MEMA.

Publication types

Review